tiprankstipranks
CStone Pharmaceuticals Advances Innovative Cancer Therapy
Company Announcements

CStone Pharmaceuticals Advances Innovative Cancer Therapy

CStone Pharmaceuticals (HK:2616) has released an update.

Don't Miss Our Christmas Offers:

CStone Pharmaceuticals has submitted a clinical trial application in Australia for its innovative trispecific antibody, CS2009, which targets PD-1, VEGFA, and CTLA-4 to combat various solid tumors. With promising preclinical results, CS2009 is positioned to potentially outperform existing therapies and expand into multi-regional trials, including China and the United States, by 2025. This development marks a significant milestone in CStone’s Pipeline 2.0 strategy, promising new hope for cancer patients.

For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App